Arsanis Biosciences Gmbh

X4 Pharmaceuticals (austria) Gmbh

Cebina Gmbh

Max-planck-gesellschaft Zur F&#xf6;rderung Der Wissenschaften E. V.

Janssen Pharmaceuticals, Inc.

Eveliqure Biotechnologies Gmbh

Gábor Nagy

Eszter Nagy

Valéria Szijárto

Adriana Badarau

Irina Mirkina

Luis Guachalla

Jolanta Lukasiewicz

Gerhild Zauner

Zoltán Magyarics

Robert Konrat

Zehra Visram

Valeria Szijárto

Bianka Prinz

Manuel Zerbs

Astrid Teubenbacher

Luis Gauchalla

Zóltan Magyarics

Lukas Stulik

Michaela Jaegerhofer

Ivana Dolezilkova

Michael Benjamin Battles

Tamás Henics

Katharina Ramoni

Tim Rollenske

Maximiliano Vasquez

Hedda Wardemann

Harald Rouha

Jolanta Katarzyna Lukasiewicz

Bianka Dominique Prinz

Valeria Szijarto

The subject relates to an isolated antibody that specifically binds to O25b antigen of multi drug resistant (MDR)strains, its medical and diagnostic use, method of producing the antibody, including an isolated nucleotide sequence, plasmids and host cells as used in the production of the antibody; and further an isolated epitope recognized the specific antibody.

MDRimmunogen

The invention refers to an isolated antibody that specifically binds to O25b antigen ofstrains comprising at least an antibody heavy chain variable region (VH), which comprises any of the CDR1 to CDR3 sequences as listed in FIG., and optionally further comprising an antibody light chain variable region (VL), which comprises any of the CDR4 to CDR6 sequences as listed in FIG., or functionally active CDR variants of any of the forgoing CDR 1-6 sequences.

specific antibodies

The invention provides for an isolated antibody that specifically recognizes a galactan-III epitope of the lipopolysaccharide (LPS) O-antigen structure of, which epitope is incorporated in galactan-III repeating units, wherein the galactan-III repeating unit is a branched galactose homopolymer of Formula (I). The invention further provides for a pharmaceutical or diagnostic preparation comprising said antibody, and a method of producing said antibody. 

Antibodies targeting a galactan-based O-antigen of K. pneumoniae

A method of treating a subject in need of anti-coronavirus treatment by providing a prophylactic or therapeutic treatment which includes an antiviral effective amount of an Azelastine compound, where the antiviral effective amount is 0.1-500 &#x3bc;g per dose. An Azelastine compound can also be used as an antiviral substance in a medicinal product for treating a biological surface to prevent coronavirus infection and/or coronavirus spread, or as a viral disinfectant.

Antiviral treatment

A method of treating a subject in need of anti-Coronavirus treatment comprising prophylactic or therapeutic treatment, with an antiviral effective amount of an Azelastine compound, wherein the antiviral effective amount is 0.1-500 &#x3bc;g per dose; use of an Azelastine compound as an antiviral substance in a medicinal product for treating a biological surface to prevent from Coronavirus infection and/or Coronavirus spread, and use of an Azelastine compound as viral disinfectant.

MDRspecific antibody

A cross-neutralizing monoclonal antibody that specifically recognizes a cross-reactive epitope of the lipopolysaccharide (LPS) antigen structure of, which is an O3b epitope, cross-reacting with an O3a epitope and an O3 epitope, wherein the antibody is characterized by specific CDR sequences or VH and VL sequences.

O3 specific antibodies

[object Object]

The subject relates to a cross-neutralizing antibody comprising at least one polyspecific binding site that binds to alpha-toxin (Hla) and at least one of the bi-component toxins of, its medical and diagnostic use, method of producing the antibody, including an isolated nucleotide sequence, plasmids and host cells as used in the production of the antibody; and further an isolated conformational epitope recognized by a specific cross-neutralizing antibody.

A live attenuatedvaccine, which is based on a roughstrain lacking LPS O-antigen which is non-invasive through a mutation of the invasion plasmid, specifically for use in the immunoprophylaxis of a subject to prevent infectious diseases, preferably enteral disease, and astrain, which is a2a strain with a deletion of the rfb F, ipa B and/or ipa C genes, as well as a recombinant plasmid vector based on a mutatedinvasion plasmid comprising a nucleotide sequence encoding at least one heterologous antigen, wherein the plasmid is mutated in at least one of the ipa B and/or ipa C genes.

Live attenuated Shigella vaccine

Growing community of inventors

Sopron, Hungary

Gábor Nagy